Animal Models of Cancer-Associated Hypercalcemia.
Kohart NA, Elshafae SM, Breitbach JT, Rosol TJ.
Vet Sci. 2017 Apr 13;4(2):21. doi: 10.3390/vetsci4020021.
Bisphosphonate nephrotoxicity.
Perazella MA, Markowitz GS.
Kidney Int. 2008 Dec;74(11):1385-93. doi: 10.1038/ki.2008.356. Epub 2008 Aug 6.
Molecular Regulation of Bone Metastasis Pathogenesis.
Wu MY, Li CJ, Yiang GT, Cheng YL, Tsai AP, Hou YT, Ho YC, Hou MF, Chu PY.
Cell Physiol Biochem. 2018;46(4):1423-1438. doi: 10.1159/000489184. Epub 2018 Apr 18.
Hypercalcemia of malignancy.
Insogna KL, Broadus AE.
Annu Rev Med. 1987;38:241-56. doi: 10.1146/annurev.me.38.020187.001325.
Incidence and pathophysiology of hypercalcemia.
Mundy GR.
Calcif Tissue Int. 1990;46 Suppl:S3-10. doi: 10.1007/BF02553287.
Clodronate news of efficacy in osteoporosis.
Nardi A, Ventura L, Cozzi L, Tonini G.
Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):33-5. doi: 10.11138/ccmbm/2016.13.1.033. Epub 2016 May 11.
Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein.
Wysolmerski JJ, Broadus AE.
Annu Rev Med. 1994;45:189-200. doi: 10.1146/annurev.med.45.1.189.
Update on the medical treatment of hypercalcemia of malignancy.
Hall TG, Schaiff RA.
Clin Pharm. 1993 Feb;12(2):117-25.
Hypercalcemia and bone resorption in malignancy.
Walls J, Bundred N, Howell A.
Clin Orthop Relat Res. 1995 Mar;(312):51-63.
Hypercalcemia affected in metastatic breast cancer patients without bone metastasis: report of three cases.
Hashizume S, Shimoda M, Yoshinami T, Abe K, Masunaga N, Sota Y, Miyake T, Tanei T, Shimazu K.
Surg Case Rep. 2022 Nov 26;8(1):210. doi: 10.1186/s40792-022-01565-9.
